Topics:

Radiation Oncology

Radiation Oncology

In the field of oncology, we are fortunate to possess a vast and ever-expanding trove of knowledge, and we now have a sufficient foundation of knowledge in many cancers to afford ourselves the luxury of striving to seek wisdom as well.

Adding thoracic radiotherapy to chemotherapy and prophylactic cranial irradiation improved 2-year survival in extensive-stage small-cell lung cancer patients.

In this review we discuss the rationale and underlying radiobiologic concepts for hypofractionation, and review the clinical trials and ASTRO guidelines supporting hypofractionated radiation in the treatment of breast cancer.

Customized more aggressive treatments should be given to patients with the worst prognosis. For most of the other breast patients, shorter and often milder treatment is also a humble victory in our daily struggle against cancer.

There is a need to learn more about the effect of hypofractionation on an individual patient’s breast cancer outcomes and tissue toxicities, based on both biologic and technical variables, so that the treatment decision is not primarily a matter of dollars and cents.

Pages

Subscribe to Radiation Oncology on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.